CAZZOLA, MARIO
 Distribuzione geografica
Continente #
NA - Nord America 10.663
EU - Europa 7.451
AS - Asia 5.230
SA - Sud America 29
Continente sconosciuto - Info sul continente non disponibili 27
AF - Africa 26
OC - Oceania 18
Totale 23.444
Nazione #
US - Stati Uniti d'America 10.563
CN - Cina 5.018
IE - Irlanda 2.215
UA - Ucraina 1.539
FI - Finlandia 1.084
DE - Germania 817
SE - Svezia 709
IT - Italia 520
GB - Regno Unito 323
FR - Francia 119
SG - Singapore 112
CA - Canada 87
RU - Federazione Russa 46
IN - India 39
BE - Belgio 31
IR - Iran 22
EU - Europa 20
AU - Australia 17
JP - Giappone 17
MU - Mauritius 17
NL - Olanda 13
BR - Brasile 10
PA - Panama 9
BO - Bolivia 8
CZ - Repubblica Ceca 8
RO - Romania 7
TR - Turchia 7
CL - Cile 6
A2 - ???statistics.table.value.countryCode.A2??? 5
AT - Austria 4
CO - Colombia 4
LV - Lettonia 4
ZA - Sudafrica 4
CH - Svizzera 3
ES - Italia 3
MX - Messico 3
NG - Nigeria 3
PL - Polonia 3
BD - Bangladesh 2
BG - Bulgaria 2
EG - Egitto 2
HK - Hong Kong 2
MN - Mongolia 2
XK - ???statistics.table.value.countryCode.XK??? 2
CR - Costa Rica 1
DK - Danimarca 1
FK - Isole Falkland (Malvinas) 1
ID - Indonesia 1
IL - Israele 1
IQ - Iraq 1
JO - Giordania 1
KR - Corea 1
LA - Repubblica Popolare Democratica del Laos 1
MY - Malesia 1
NZ - Nuova Zelanda 1
QA - Qatar 1
TW - Taiwan 1
Totale 23.444
Città #
Chandler 2.220
Dublin 2.212
Jacksonville 1.998
Nanjing 1.553
Boardman 781
Ashburn 701
Nanchang 613
Princeton 517
Lawrence 496
Wilmington 489
Hebei 462
Shenyang 453
Changsha 392
Jiaxing 371
Medford 350
Beijing 274
Hangzhou 240
Helsinki 227
Tianjin 227
Ann Arbor 206
New York 134
Milan 129
Woodbridge 110
Norwalk 96
Shanghai 92
Verona 76
Singapore 73
Toronto 71
Pavia 69
Seattle 65
Falls Church 54
Jinan 51
Fairfield 42
Los Angeles 39
Washington 38
Des Moines 37
Kunming 34
Ningbo 33
Zhengzhou 33
Brussels 31
Houston 30
Taizhou 28
Chicago 26
Tappahannock 21
Guangzhou 20
Auburn Hills 17
Rome 14
Tokyo 14
Dearborn 13
Lanzhou 13
San Francisco 13
Borås 12
Pune 12
Redwood City 12
Florence 11
Fuzhou 11
Goiânia 8
La Paz 8
Leawood 8
Munich 8
Panama City 8
Changchun 7
Naples 7
Dallas 6
Falkenstein 6
Haikou 6
Kemerovo 6
Melbourne 6
Orange 6
Monmouth Junction 5
Novokuznetsk 5
Trento 5
Ardabil 4
Brignano Gera D'adda 4
Brno 4
Gallarate 4
Manchester 4
Montespertoli 4
Napoli 4
Ottawa 4
Reston 4
Zanjan 4
Andover 3
Bari 3
Bovisio Masciago 3
Canberra 3
Catania 3
Delhi 3
Forest City 3
Isfahan 3
Redmond 3
Rochester 3
Saint Paul 3
San Luis Obispo 3
Taranto 3
Wayne 3
Yuncheng 3
Alghero 2
Antony 2
Arcore 2
Totale 16.552
Nome #
Anemia associata ad endocrinopatie. 93
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 92
Familial-skewed X-chromosome inactivation as a predisposing factor for late-onset X-linked sideroblastic anemia in carrier females. 89
Inhibition of c-ABL expression in hematopoietic progenitor cells using antisense oligodeoxynucleotides 87
WALDENSTROM'S HYPERGLOBULINEMIC PURPURA IN HLA IDENTICAL SISTERS. 87
Cord blood-derived hematopoietic progenitor cells: in vitro response to hematopoietic growth factors and their recruitment into the S-phase of the cell cycle. 84
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts 83
Further concerns about the medical risks of blood doping. 80
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 80
Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes. 79
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. 79
A case of persistent eosinophilia 79
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndrome 78
Hereditary hyperferritinemia-cataract syndrome: relationship between phenotypes and specific mutations in the iron-responsive element of ferritin light-chain mRNA. 77
Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations 77
Microcytic anemia in rheumatoid arthritis. Relationship with activity and duration of the disease and iron status. 77
Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug 75
USE OF A MONOCLONAL ANTIBODY AGAINST HUMAN HEART FERRITIN FOR EVALUATING ACIDIC FERRITIN CONCENTRATION IN HUMAN SERUM 75
Circulating endothelial cell separation from peripheral blood of patients affected by myelodysplastic syndromes: Preliminary results obtained by a new immunomagnetic procedure 74
CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis 74
Blast phase of essential thrombocythemia: A single center study. 72
ANALYSIS OF THE MITOCHONDRIAL FERRITIN PHYSIOPATHOLOGICAL ROLE IN SIDEROBLASTIC ERYTHROPOIESIS 72
A model for analysing the cost of autologous peripheral blood progenitor cell (PBPC) transplantation 72
Not just clonal expansion of hematopoietic cells, but also activation of their progeny in the pathogenesis of myeloproliferative disorders 71
Tie2 expressing monocytes in the spleen of patients with primary myelofibrosis 71
A prognostic model for predicting the impact of comorbidities on survival of patients with myelodysplastic syndromes 70
Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. 70
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis 70
Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. 69
A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron 69
Evidence for a polyclonal nature of the cell infiltrate in sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). 69
Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2. 69
Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia 68
Gain of function, loss of control - a molecular basis for chronic myeloproliferative disorders 68
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders 68
Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes 68
Classification and prognostic evaluation of myelodysplastic syndromes 68
Intracellular calcium deposits and store operated calcium entry in CD34+ cells from patients with myelofibrosis carrying a CALR mutation 68
Clinical severity and thermodynamic effects of iron-responsive element mutations in hereditary hyperferritinemia-cataract syndrome 67
Deferoxamine in thalassemia major. 67
JAK2 (V617F) mutation in healthy individuals 67
A screen for RAS mutations in individuals at risk of secondary leukaemia due to occupational exposure to petrochemicals. 67
Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following intensified, accelerated CEE (cyclophosphamide, epirubicin, etoposide) chemotherapy: cytokinetic effects on bone marrow hematopoietic progenitors. 66
Leukemia risk models in primary myelofibrosis: an International Working Group study. 66
Policitemia vera. 66
JAK inhibitor in CALR-mutant myelofibrosis 66
Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. 66
Effect of recombinant gamma interferon on the proliferative activity of cultured leukemic cells. 65
Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production 65
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms 65
Effects of desferrrioxamine on normal and leukemic human hematopoietic cell growth: in vitro and in vivo studies 64
A modified high-dose dexamethasone regimen for primary systemic amyloidosis 64
Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders 64
The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. 64
Abnormal splenic uptake of red cells in long-lasting iron deficiency anemia due to self-induced bleeding (factitious anemia). 64
VASCULAR ENDOTHELIAL GROWTH FACTOR OVEREXPRESSION IN BONE MARROW CELLS FROM PATIENTS WITH MYELODYSPLASTIC SYNDROME: BIOLOGICAL AND CLINICAL RELEVANCE 64
A translational link between Fe and Epo 64
Effects of mitochondrial ferritin overexpression in normal and sideroblastic erythroid progenitors. 64
Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms 64
Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms. 64
MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance 64
Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure 64
Classification of anaemia on the basis of ferrokinetic parameters. 64
Tumor necrosis factor alpha down-regulates c-myc mRNA expression and induces in vitro monocytic differentiation in fresh blast cells from patients with acute myeloblastic leukemia. 64
Clinical significance of somatic mutation in unexplained blood cytopenia 64
Translational pathophysiology: a novel molecular mechanism of human disease 63
Hyperferritinemia-cataract syndrome associated to the HFE gene mutation. Two new Spanish families and a new mutation (A37T: "Zaragoza") 63
Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis 63
Cell kinetics of CD34-positive hematopoietic cells following chemotherapy plus colony-stimulating factors in advanced breast cancer. 63
Haploinsufficiency of RPS14 in 5q− syndrome is associated with deregulation of ribosomal- and translation-related genes 63
Erythrokinetics and mechanisms of anaemia in hereditary elliptocytosis and hereditary ovalocytosis. 63
Ittero. 63
A linkage between hereditary hyperferritinaemia not related to iron overload and autosomal dominant congenital cataract. 62
X-linked Wiskott-Aldrich syndrome in a girl. 62
Mitochondrial ferritin: a new player in iron metabolism 62
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation. 62
Myelodysplastic syndromes: recent advances 61
Genetic disorders of iron overload and the novel ''ferroportin disease'' 61
An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression. 61
Basic and acidic isoferritins in the serum of patients with Hodgkin's disease. 61
A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis. 61
Policitemia vera. 61
Accelerated erythroid repopulation with no stem-cell competition effect in children treated with recombinant human erythropoietin after allogeneic bone marrow transplantation 61
Clinical and biological implications of driver mutations in myelodysplastic syndromes 61
Natural history of juvenile haemochromatosis 60
Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes 60
Studio morfologico e citochimico dei megacariociti in 25 casi di displasie emopoietiche. 60
Hematologic passport for athletes competing in endurance sports: a feasibility study. 60
Biochemical and genetic defects underlying human congenital hypotransferrinemia 60
Pincered red cells and hereditary spherocytosis. 60
Diabetes insipidus in the preleukaemic phase of acute non-lymphocytic leukaemia. A monosomy 7-associated condition? 60
Expression of adhesion molecules and functional stimulation in human neutrophils: modulation by GM-CSF and role of the Bcr gene. 60
Sindrome anemica. 60
A chronic lymphoproliferative disorder 60
Revised international prognostic scoring system for myelodysplastic syndromes 60
Soluble transferrin receptor as a potential determinant of iron loading in congenital anaemias due to ineffective erythropoiesis 59
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes 59
PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia 59
Interferons as biologic modulators of hematopoietic cell proliferation and differentiation. 59
An improved method for liquid scintillation counting of 59Fe in ferrokinetic studies. 59
Totale 6.756
Categoria #
all - tutte 92.678
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 92.678


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.254 0 2.556 10 285 8 316 74 356 30 468 145 6
2020/20212.860 335 257 76 300 7 378 31 453 126 439 374 84
2021/20222.194 32 8 67 39 101 130 40 119 120 93 341 1.104
2022/20236.374 745 374 48 520 634 706 3 404 2.642 33 165 100
2023/20242.279 254 448 96 207 220 623 65 137 15 53 60 101
2024/2025710 156 554 0 0 0 0 0 0 0 0 0 0
Totale 23.984